2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.
Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker of response for immunotherapy in melanoma.
Taking a broad look at the tumor microenvironment via gene expression profiling can provide insight into which patients with melanoma may respond better from immunotherapy, says Luke. Patients who have a T-cell inflamed tumor microenvironment are much more immunotherapy responsive, while patients who have no lymphocytes in their tumor microenvironment will most likely not respond to immunotherapy.
A useful clinical grade test could identify patients who are the most highly inflamed and are therefore good candidates for anti-PD-1 antibodies alone, says Luke. It could also identify those who have inflammation in the tumor microenvironment, and perhaps need the upfront combination of anti-CTLA-4 and PD-1 blocking agents, he adds.
<<<
Related Content: